The primary reason that a clinical trial fails in the United States today is because investigators cannot find enough patients to participate. Quinton Maidment, Vice President of The Bliss Group and a leader in clinical trial recruitment, explains to Urban Health Today how his organization helps address this issue and why diversity in clinical trials is critical to their success.
Advertisement
C5a, IL-9, and apo A-IV were identified as potential biomarkers for predicting CSU severity.
Autologous serum skin test positivity was associated with a delayed response to omalizumab treatment in patients with CSU.
For people with metastatic cancer, the constant focus on cure can create a sense of isolation from the cancer community.
A study highlighted the underutilization of patient-reported outcome measures in the management of AD and CU.
Disparities in access to omalizumab for patients with CSU significantly impact treatment patterns and health outcomes.
CSU negatively affects quality of life, and patients with CSU are more likely to have worse sleep.
Expert Interviews
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
Urban Health Weekly
Gillian Barclay on the Oral Health-Overall Health Connection Among Children
Andrew Hertler, MD, talks about the importance of prophylactic mastectomy for individuals carrying high-risk gene mutations.
Adrelia Allen, PharmD, discusses the urgent push for diversity in clinical trials.
Dr. Andrew Hertler discusses updated pancreatic cancer screening guidelines that include BRCA 1 & BRCA 2 gene mutations.
